Disc Medicine, Inc. (NASDAQ:IRON) Receives $53.78 Average Target Price from Analysts

Disc Medicine, Inc. (NASDAQ:IRON) has been assigned an average recommendation of “Buy” from the ten analysts that are presently covering the firm, Marketbeat reports. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $53.78.

A number of equities research analysts have recently weighed in on the company. BMO Capital Markets boosted their price target on Disc Medicine from $40.00 to $70.00 in a research note on Monday, June 12th. Raymond James raised Disc Medicine from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $50.00 to $75.00 in a research report on Friday, June 9th. HC Wainwright lifted their price target on Disc Medicine from $66.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, August 14th. Cantor Fitzgerald increased their price objective on Disc Medicine from $45.00 to $65.00 in a report on Friday, June 9th. Finally, Stifel Nicolaus lifted their target price on Disc Medicine from $50.00 to $65.00 in a report on Friday, June 23rd.

Insider Activity at Disc Medicine

In other Disc Medicine news, insider William Jacob Savage sold 4,384 shares of the company’s stock in a transaction dated Wednesday, June 28th. The shares were sold at an average price of $49.98, for a total value of $219,112.32. Following the completion of the transaction, the insider now owns 15,941 shares in the company, valued at $796,731.18. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, insider William Jacob Savage sold 4,384 shares of the business’s stock in a transaction that occurred on Wednesday, June 28th. The stock was sold at an average price of $49.98, for a total value of $219,112.32. Following the completion of the sale, the insider now directly owns 15,941 shares in the company, valued at $796,731.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian Richard Macdonald sold 4,324 shares of the company’s stock in a transaction that occurred on Friday, June 30th. The stock was sold at an average price of $45.05, for a total value of $194,796.20. Following the transaction, the insider now directly owns 12,876 shares of the company’s stock, valued at $580,063.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,634,728 shares of company stock worth $77,786,351. 4.71% of the stock is owned by company insiders.

Hedge Funds Weigh In On Disc Medicine

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IRON. Ameritas Investment Partners Inc. acquired a new position in shares of Disc Medicine during the 2nd quarter worth about $28,000. Bank of America Corp DE increased its stake in Disc Medicine by 134,000.0% during the 1st quarter. Bank of America Corp DE now owns 2,682 shares of the company’s stock worth $57,000 after buying an additional 2,680 shares in the last quarter. Citigroup Inc. acquired a new position in shares of Disc Medicine during the fourth quarter valued at approximately $101,000. California State Teachers Retirement System purchased a new position in shares of Disc Medicine in the second quarter valued at approximately $114,000. Finally, Barclays PLC boosted its stake in shares of Disc Medicine by 2,709.5% in the first quarter. Barclays PLC now owns 5,619 shares of the company’s stock worth $119,000 after acquiring an additional 5,419 shares during the last quarter.

Disc Medicine Price Performance

NASDAQ IRON opened at $48.91 on Friday. Disc Medicine has a one year low of $11.80 and a one year high of $57.70. The company’s 50-day simple moving average is $51.05 and its two-hundred day simple moving average is $39.96.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Friday, August 11th. The company reported ($0.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.12. Analysts predict that Disc Medicine will post -3.47 earnings per share for the current year.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, operates as a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.